Lupin has received tentative approval for its Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Eli Lilly and company's Cialis Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg.
It is indicated for the treatment of erectile dysfunction, the signs and symptoms of benign prostatic hyperplasia and erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia. Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg had annual sales of approximately $1949.2 million in the US (IQVIA MAT April 2018).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
